Anbio Biotechnology (NNNN) Equity Average (2024 - 2025)
Anbio Biotechnology's quarterly Equity Average came in at $23.7 million in Q4 2025, up 47.91% year-on-year from $16.0 million in Q4 2024, and up 47.91% quarter-over-quarter from $16.0 million in Q4 2024.
Anbio Biotechnology has reported Equity Average for 2 years, with the latest figure at $23.7 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 47.91% year-over-year to $23.7 million; the trailing twelve-month figure through Dec 2025 stood at $23.7 million (up 47.91% YoY), and the FY2025 full-year result was $23.7 million, up 47.91% from the prior year.
- Equity Average for Q4 2025 stood at $23.7 million, up from $16.0 million in the prior quarter.
- The five-year high for Equity Average was $23.7 million in Q4 2025, with the low at $16.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | 17.71 Bn |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | 20.42 Bn |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | 6.41 Bn |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | 3.08 Bn |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | 5.01 Bn |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | 8.30 Bn |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | 4.10 Bn |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | 6.07 Bn |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | 2.65 Bn |
| 10 | Anbio Biotechnology | 1.32 Bn | 1.31 Bn | - | 23.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.67 Mn |
| Dec 31, 2024 | 16.01 Mn |